艾迪注射液联合NP方案治疗晚期非小细胞肺癌临床观察

Clinical observation of Aidi-injection combining vinorelbine and cisplation in the treatment of advanced non-small cell lung cancer

目的艾迪注射液联合化疗治疗晚期非小细胞肺癌的疗效与毒副反应。方法将86例患者采用信封抽签法随机分为艾迪注射液+国产长春瑞宾(盖诺NVB)+顺铂(DDP)为联合组NVB+DDP为化疗组。结果联合组47例有效率31.91%(15/47),化疗组30.76%(12/39),两组差异无统计学意义,P=0.9946;联合组KPS改善率29.78%(14/47)明显高于化疗组12.82%(5/39),P=0.0199;联合组Ⅲ～Ⅳ白细胞下降21.27%(10/47),明显低于化疗组56.41%(22/39),P=0.002;联合组在治疗前后比较,NK细胞活性升高,P=0.000。结论艾迪注射液配合化疗治疗晚期非小细胞肺癌可改善生活质量,减轻毒副反应。

OBJECTIVE:To observe the clinical effect a nd toxicity of Aidi-injection combining chemotherapy in the treatment of advanced non-small lung cancer(NSCLC).METHODS:86 Patients with NS CLC were randomly divided into Aidi-injection combining NP (NVB+DDP) regimen gr oup (Combination group) and NP regimen group (Chemotherapy group).RES ULTS:Response rate was 31.91%(15/47) for the Combination group,or3 0.76%(12/39) for the Chemotherapy group, showing no significant difference be tween the groups(P=0.9946).The improvement rate of KPS score for the Combi nation group was12.82%(5/39) higher than the rate, 29.78%(14/47) in the Ch emotherapy group (P=0.0199). Grades Ⅲ and Ⅳ of neutropenia for the Combi nation group were 21.27%(10/47),lower than that for the Chemotherapy group 5 6.41%(22/39)(P=0.002).The levels of NK cells of the Combination group we re increased after curation (P=0.000).CONCLUSIONS:Ai di-injection combining chemotherapy in the treatment of NSCLC can improve life quality ,lessen the toxicity and increase the levels of NK cells.[